Skip to main navigation
Ardelyx logo2
  • Who We Are
  • Products
  • Science & Pipeline
  • Patients & Families
  • Medical Professionals
  • Investors
  • Join Us
  • MENU
  • HOME
Select Page

News & Events

  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR
  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR

News & Events

Press Releases
May 17, 2022
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
Read More
May 16, 2022
Ardelyx, Inc. Reports Employment Inducement Grants
Read More
May 5, 2022
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
Read More
View All Press Releases
Events & Presentations
May 5, 2022 at 4:30 PM EDT
Ardelyx Q1 2022 Earnings Call
Mar 9, 2022 at 10:30 AM EST
Cowen 42nd Annual Health Care Conference
Feb 28, 2022 at 4:30 PM EST
Ardelyx Q4 2021 Earnings Call
View All Events
FAQs
Email Alerts
Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com

  • Follow
  • Follow

© 2022 Ardelyx®
Terms & Conditions · Privacy Policy
Expanded Access · Forward Looking Statements

SITE DESIGN BY D&CO
  • Facebook
  • LinkedIn
  • Twitter
  • RSS